2. シグナル伝達
  3. Immunology/Inflammation
  4. Interleukin Related
  5. IL-6 Isoform
  6. IL-6 Inhibitor

IL-6 Inhibitor

IL-6 Inhibitors (314):

製品番号 製品名 製品効果 純度
  • HY-119575
    Tetramethyluric acid Inhibitor 99.63%
    Tetramethyluric acid (1,3,7,9-Tetramethyluric acid) is an orally active purine alkaloid in Coffea species and Camellia kucha. Tetramethyluric acid exhibits antiviral, and anti-inflammatory activity. Tetramethyluric acid can be used for the research of inflammation disease, and influenza virus infection.
  • HY-B1350A
    Fusidic acid sodium salt Inhibitor 99.64%
    Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice.
  • HY-N2434
    [10]-Shogaol Inhibitor 99.78%
    [10]-Shogaol is an orally active antioxidant. [10]-Shogaol can be extracted from ginger (Zingiber officinale). [10]-Shogaol1 inhibits COX-2 with an IC50 value of 7.5 μM. [10]-Shogaol inhibits the production of proinflammatory cytokines (IL-1β, IL-6). [10]-Shogaol inhibits NF-κB phosphorylation. [10]-Shogaol has anti-inflammatory effects. [10]-Shogaol has anticancer effects against Docetaxel (HY-B0011)-resistant prostate cancer. [10]-Shogaol exhibits larvicidal activity against L5 larvae of Angiostrongylus cantonensis.
  • HY-128731
    5-Methoxy-DL-tryptophan Inhibitor 99.32%
    5-Methoxy-DL-tryptophan is a metabolite. 5-Methoxy-DL-tryptophan reduces LPS (HY-D1056)-induced release of IL-6. 5-Methoxy-DL-tryptophan has anti-inflammatory effects. 5-Methoxy-DL-tryptophan can be used in the study of atherosclerosis.
  • HY-P990242
    Anti-Mouse Galectin-9 Antibody (RG9-1) Inhibitor
    Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4+ and CD8+ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia.
  • HY-N2443
    Tribuloside Inhibitor 99.26%
    Tribuloside is a flavonoid and PDE4 inhibitor (IC50: 6 μM). Tribuloside exhibits antibacterial and antioxidant activities, capable of scavenging DPPH free radicals. Tribuloside also promotes melanogenesis. Tribuloside can be used in the research of hypopigmentary diseases, sun protection, and inflammatory diseases such as acute lung injury.
  • HY-124750
    NecroX-7 Inhibitor 99.69%
    NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research.
  • HY-117878
    ML345 Inhibitor 99.37%
    ML345 is a potent and selective inhibitor of insulin-degrading enzyme (IDE) and NLRP3, with an IC50 of 188 nM against IDE. ML345 targets the Cys819 residue of IDE to inhibit IDE. ML345 selectively binds to NLRP3 in a non-covalent manner. ML345 inhibits inflammatory cytokines (IL-1β, IL-6) and exhibits potent anti-inflammatory activity. ML345 exerts a protective effect against miscarriage.
  • HY-N2440
    Gypenoside A Inhibitor 99.79%
    Gypenoside A is an orally active triterpenoid compound that can be isolated from Gynostemma pentaphyllum. Gypenoside A has anti-inflammatory and antioxidant activities. Gypenoside A also has a certain protective effect on cardiomyocytes and can inhibit apoptosis. Gypenoside A can be used in the research of cardiovascular diseases and inflammation-related diseases.
  • HY-N2481
    Oroxylin A-7-O-glucuronide Inhibitor 99.83%
    Oroxylin A-7-O-glucuronide (oroxyloside) is an orally active flavonoid glucuronide and metabolite of Oroxylin A (HY-N0560). Oroxylin A-7-O-glucuronide can be extracted from the dried root of Scutellaria baicalensis. Oroxylin A-7-O-glucuronide exhibits prolyl oligopeptidase inhibitory activity. Oroxylin A-7-O-glucuronide inhibits the JNK pathway, upregulates PPARγ, and inhibits NF-κB p65 nuclear translocation. Oroxylin A-7-O-glucuronide reduces cytokine (IL-1β, IL-6) production. Oroxylin A-7-O-glucuronide exhibits anti-angiogenic, anti-tumor (glioma, liver cancer), anti-inflammatory, and hepatoprotective activities.
  • HY-W1000105
    Geranial Inhibitor 99.51%
    Geranial is an aromatic compound. It can be isolated from the fruits of Litsea cubeba Lour and the rhizomes of ginger (Zingiber officinale). Geranial inhibits LPS-induced phosphorylation of ERK1/2, JNK1/3 and IκB in macrophages. It suppresses the secretion of IL-1β, TNF-α and IL-6, as well as the expression of pro-IL-1β, iNOS and COX-2. Geranial increases ROS. It can be used in the research of inflammatory diseases.
  • HY-122822
    GSK699 Inhibitor 98.80%
    GSK699 is a KAT2A/B/PCAF/GCN5 PROTAC degrader. GSK699 induces proteasome-dependent degradation of KAT2A, KAT2B, PCAF and GCN5, regulates the histone acetyltransferase activity of the SAGA complex, and reduces the level of histone H3K9ac. GSK699 inhibits the growth of neuroblastoma, acute myeloid leukemia and small cell lung cancer cells. GSK699 reduces the production of inflammatory cytokines and chemokines, and impairs LPS-stimulated immune cell responses. GSK699 is applicable to research related to acute myeloid leukemia, small cell lung cancer, neuroblastoma and inflammatory diseases.
  • HY-N6066
    Praeruptorin E Inhibitor 99.83%
    Praeruptorin E is an orally active pyranocoumarin compound. Praeruptorin E can be isolated from the dried roots of Peucedanum praeruptorum Dunn. Praeruptorin E reduces the expression of NF-κB. Praeruptorin E upregulates the expression of PXR and CYP3A4. Praeruptorin E inhibits Th2 cytokines, TNF-α, IL6, MPO, and blocks the Ca2+ slow channel. Praeruptorin E promotes pulmonary tissue repair and relaxes porcine coronary artery strips. Praeruptorin E protects mice from lipopolysaccharide- and hydrochloric acid-induced acute lung injury. Praeruptorin E can be used in studies related to asthma and acute lung injury.
  • HY-139588
    Vemircopan Inhibitor 98.61%
    Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria.
  • HY-P99012
    Clazakizumab Inhibitor ≥99.0%
    Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection.
  • HY-N0631
    Cornuside Inhibitor 99.99%
    Cornuside is an iridoid glycoside with anti-allergic, anti-inflammatory, and neuroprotective activities. Cornuside exerts anti-allergic activity by downregulating the p38 MAPK, JNK, and NF-κB signaling pathways, and inhibits IgE-mediated histamine release from mast cells. Cornuside improves cognitive impairment in mice by inhibiting BACE1 activity (IC50 = 55.84 μg/mL) and enhancing ChAT activity. Cornuside inhibits LPS (HY-D1056)-induced inflammatory mediators, including iNOS, COX-2, PGE2, TNF-α, IL-6, and IL-1β, by suppressing NF-κB activation.
  • HY-125740
    Malvidin-3-glucoside chloride Inhibitor 99.87%
    Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health.
  • HY-N2542
    Tubeimoside III Inhibitor 99.91%
    Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD50 of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases.
  • HY-129139
    Cyanidin-3-O-arabinoside Inhibitor
    Cyanidin-3-O-arabinoside is a p38 MAPK phosphorylation inhibitor. Cyanidin-3-O-arabinoside reduces the expression of VDAC1, inhibits mtROS accumulation, reverses cellular senescence, blocks excessive mitochondrial calcium influx, reduces the formation of mitochondria-associated endoplasmic reticulum membranes, and suppresses the VDAC1-IP3R1 interaction. Cyanidin-3-O-arabinoside activates hair follicle stem cell proliferation and improves the condition of slowed hair growth. Cyanidin-3-O-arabinoside is applicable to research related to colon cancer and androgenetic alopecia.
  • HY-171034
    PQA-18 Inhibitor 99.62%
    PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens as well as alleviates dermatitis in mice.